TIDMAVCT

RNS Number : 9195M

Avacta Group PLC

25 January 2016

25 January 2016

Avacta Group plc

("Avacta" or "the Group" or "the Company")

Result of Annual General Meeting

Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and research reagents, announces that at the Annual General Meeting held earlier today, all resolutions were duly passed.

Following approval of the resolution relating to the consolidation of 1 new ordinary share of 10p each for every 100 existing ordinary shares of 0.1p each, every 100 existing ordinary shares of 0.1p each will be consolidated into 1 new ordinary share of 10p each.

The share consolidation is expected to become effective at 8.00am on 26 January 2016.

Enquiries:

 
 Avacta Group plc                          Tel: +44 (0) 
  Alastair Smith, Chief Executive           844 414 0452 
  Officer                                   www.avacta.com 
  Tony Gardiner, Chief Financial 
  Officer 
 Numis Securities Limited                  Tel: +44 (0) 
  Michael Meade / Freddie Barnfield         207 260 1000 
  - Nominated Adviser                       www.numiscorp.com 
  James Black - Corporate Broking 
 
  WG Partners                               Tel: +44 (0) 
  David Wilson                              203 705 9318 
  Nigel Barnes                              Tel: +44 (0) 
  Claes Spang                               203 705 9217 
                                            www.wgpartners.co.uk 
 Media Enquiries                           Tel: +44 (0) 
  FTI Consulting                            203 727 1000 
  Simon Conway / Natalie Garland-Collins    avacta@fticonsulting.com

Notes to Editors

Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer(R) technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $50bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

Avacta has a pre-clinical biotech development programme with an in-house focus on oncology and bleeding disorders as well as several partnered development programmes. Avacta is commercialising Affimer reagents through custom Affimer services to provide bespoke solutions to customers and via a growing on-line catalogue of Affimer reagents.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGPGUCWGUPQGAA

(END) Dow Jones Newswires

January 25, 2016 10:35 ET (15:35 GMT)

Avacta (LSE:AVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Avacta Charts.
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Avacta Charts.